Amy J. Ramsey

Amy J. Ramsey

Auto-generated profile, based on publicly available information

Amy J. Ramsey

University of Toronto

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JKJannet Kocerha
Jannet Kocerha
MFMohammad Ali Faghihi
Mohammad Ali Faghihi
MLMiguel Lopez-Toledano
Miguel Lopez-Toledano
JHJia Huang
Jia Huang
ARAmy J. Ramsey
Amy J. Ramsey
CWClaes Wahlestedt
Claes Wahlestedt
N -methyl- d -aspartate (NMDA) glutamate receptors are regulators of fast neurotransmission and synaptic plasticity in the brain. Disruption of NMDA-mediated glutamate signaling has been linked to behavioral deficits displayed in psychiatric disorders such as schizophrenia. Recently, noncoding RNA molecules such as microRNAs (miRNAs) have emerged as critical regulators of neuronal functions. Here we show that pharmacological (dizocilpine) or genetic (NR1 hypomorphism) disruption of NMDA receptor signaling reduces levels of a brain-specific miRNA, miR-219, in the prefrontal cortex (PFC) of mice. Consistent with a role for miR-219 in NMDA receptor signaling, we identify calcium/calmodulin-dependent protein kinase II γ subunit (CaMKIIγ), a component of the NMDA receptor signaling cascade, as a target of miR-219. In vivo inhibition of miR-219 by specific antimiR in the murine brain significantly modulated behavioral responses associated with disrupted NMDA receptor transmission. Furthermore, pretreatment with the antipsychotic drugs haloperidol and clozapine prevented dizocilpine-induced effects on miR-219. Taken together, these data support an integral role for miR-219 in the expression of behavioral aberrations associated with NMDA receptor hypofunction.

1 September 2006 in Neuron
Verified
Journal Article
Closed access
VPVania F. Prado
Vania F. Prado
CMCristina Martins-Silva
Cristina Martins-Silva
BCBraulio M. de Castro
Braulio M. de Castro
RLRicardo F. Lima
Ricardo F. Lima
DBDaniela M. Barros
Daniela M. Barros
MPMarco A.M. Prado
Marco A.M. Prado

18 March 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ASAli Salahpour
Ali Salahpour
ARAmy J. Ramsey
Amy J. Ramsey
IMIvan O. Medvedev
Ivan O. Medvedev
BKBrian Kile
Brian Kile
TSTatyana D. Sotnikova
Tatyana D. Sotnikova
MCMarc G. Caron
Marc G. Caron
The dopamine transporter (DAT) plays a key role in the regulation of dopaminergic signaling wherein it controls both the spatial and temporal actions of dopamine. Here we evaluated the behavioral and neurochemical consequences of increased DAT function by generating DAT transgenic mice (DAT-tg) that overexpress the transporter. These mice were generated by pronuclear injection of a bacterial artificial chromosome containing the mouse DAT locus, yielding an anatomical expression pattern of DAT-tg identical to WT. In DAT-tg mice there is a 3-fold increase in the levels of total and membrane-expressed DAT, but synaptic plasma membrane fractions of DAT-tg mice show only a 30% increase in transporter levels. Functional studies reveal that in the DAT-tg animals there is a 50% increase in the rate of dopamine (DA) uptake resulting in extracellular levels of DA that are decreased by ≈40%. Behaviorally, DAT-tg animals display similar locomotor stimulation when treated with DAT blockers such as GBR12909, methylphenidate, and cocaine. However, these mice demonstrate markedly increased locomotor responses to amphetamine compared with WT animals. Furthermore, compared with controls, there is a 3-fold greater increase in the amount of DA released by amphetamine in DAT-tg mice that correlates with the 3-fold increase in protein expression. Finally, DAT-tg animals show reduced operant responding for natural reward while displaying preference for amphetamine at much lower doses (0.2 and 0.5 mg/kg) than WT mice (2 mg/kg). These results suggest that overexpression of DAT leads to a marked increase in sensitivity to psychomotor and rewarding properties of amphetamine.

1 February 2015 in Neurobiology of Disease
Verified
Journal Article
Closed access
SMS.T. Masoud
S.T. Masoud
LVL.M. Vecchio
L.M. Vecchio
YBY. Bergeron
Y. Bergeron
MHM.M. Hossain
M.M. Hossain
LNL.T. Nguyen
L.T. Nguyen
ASAli Salahpour
Ali Salahpour

25 September 2001 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Raul R GainetdinovRaul R Gainetdinov
Raul R Gainetdinov
AMAmy R. Mohn
Amy R. Mohn
LBLaura M. Bohn
Laura M. Bohn
MCMarc G. Caron
Marc G. Caron
In the brain, dopamine exerts an important modulatory influence over behaviors such as emotion, cognition, and affect as well as mechanisms of reward and the control of locomotion. The dopamine transporter (DAT), which reuptakes the released neurotransmitter into presynaptic terminals, is a major determinant of the intensity and duration of the dopaminergic signal. Knockout mice lacking the dopamine transporter (DAT-KO mice) display marked changes in dopamine homeostasis that result in elevated dopaminergic tone and pronounced locomotor hyperactivity. A feature of DAT-KO mice is that their hyperactivity can be inhibited by psychostimulants and serotonergic drugs. The pharmacological effect of these drugs occurs without any observable changes in dopaminergic parameters, suggesting that other neurotransmitter systems in addition to dopamine might contribute to the control of locomotion in these mice. We report here that the hyperactivity of DAT-KO mice can be markedly further enhanced when N- methyl- d -aspartate receptor-mediated glutamatergic transmission is blocked. Conversely, drugs that enhance glutamatergic transmission, such as positive modulators of l -α-amino-3-hydroxy-5-methylisoxazole-4-propionate glutamate receptors, suppress the hyperactivity of DAT-KO mice. Interestingly, blockade of N- methyl- d -aspartate receptors prevented the inhibitory effects of both psychostimulant and serotonergic drugs on hyperactivity. These findings support the concept of a reciprocal functional interaction between dopamine and glutamate in the basal ganglia and suggest that agents modulating glutamatergic transmission may represent an approach to manage conditions associated with dopaminergic dysfunction.

27 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JJJulie Jézéquel
Julie Jézéquel
EJEmily M. Johansson
Emily M. Johansson
JDJulien P. Dupuis
Julien P. Dupuis
VRVéronique Rogemond
Véronique Rogemond
HGHélène Gréa
Hélène Gréa
LGLaurent Groc
Laurent Groc
The identification of circulating autoantibodies against neuronal receptors in neuropsychiatric disorders has fostered new conceptual and clinical frameworks. However, detection reliability, putative presence in different diseases and in health have raised questions about potential pathogenic mechanism mediated by autoantibodies. Using a combination of single molecule-based imaging approaches, we here ascertain the presence of circulating autoantibodies against glutamate NMDA receptor (NMDAR-Ab) in about 20% of psychotic patients diagnosed with schizophrenia and very few healthy subjects. NMDAR-Ab from patients and healthy subjects do not compete for binding on native receptor. Strikingly, NMDAR-Ab from patients, but not from healthy subjects, specifically alter the surface dynamics and nanoscale organization of synaptic NMDAR and its anchoring partner the EphrinB2 receptor in heterologous cells, cultured neurons and in mouse brain. Functionally, only patients’ NMDAR-Ab prevent long-term potentiation at glutamatergic synapses, while leaving NMDAR-mediated calcium influx intact. We unveil that NMDAR-Ab from psychotic patients alter NMDAR synaptic transmission, supporting a pathogenically relevant role.